• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

晚期蕈样肉芽肿:信号转导和转录激活因子3、核因子κB及活化T细胞核因子通路的作用

Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways.

作者信息

Pérez C, Mondéjar R, García-Díaz N, Cereceda L, León A, Montes S, Durán Vian C, Pérez Paredes M G, González-Morán A, Alegre de Miguel V, Sanz Anquela J M, Frias J, Limeres M A, González L M, Martín Dávila F, Beltrán M, Mollejo M, Méndez J R, González M A, González García J, López R, Gómez A, Izquierdo F, Ramos R, Camacho C, Rodriguez-Pinilla S M, Martínez N, Vaqué J P, Ortiz-Romero P L, Piris M A

机构信息

Translational Hematopathology, Instituto de Investigación Marqués de Valdecilla, IDIVAL, Santander, Spain.

Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain.

出版信息

Br J Dermatol. 2020 Jan;182(1):147-155. doi: 10.1111/bjd.18098. Epub 2019 Jul 25.

DOI:10.1111/bjd.18098
PMID:31049933
Abstract

BACKGROUND

The malignant mechanisms that control the development of cutaneous T-cell lymphoma (CTCL) are beginning to be identified. Recent evidence suggests that disturbances in specific intracellular signalling pathways, such as RAS-mitogen-activated protein kinase, T-cell receptor (TCR)-phospholipase C gamma 1 (PLCG1)-nuclear factor of activated T cells (NFAT) and Janus kinase (JAK)-signal transducer and activator of transcription (STAT), may play an essential role in the pathogenesis of CTCL.

OBJECTIVES

To investigate the mechanisms controlling disease development and progression in mycosis fungoides (MF), the most common form of CTCL.

METHODS

We collected 100 samples that were submitted for diagnosis of, or a second opinion regarding, MF between 2001 and 2018, 80% of which were in the early clinical stages of the disease. Formalin-fixed paraffin-embedded tissues were used for histological review and to measure the expression by immunohistochemistry of surrogate markers of activation of the TCR-PLCG1-NFAT, JAK-STAT and NF-κB pathways. Folliculotropism and large-cell transformation were also examined.

RESULTS

NFAT and nuclear factor kappa B (NF-κB) markers showed a comparable activation status in early and advanced stages, while STAT3 activation was more frequent in advanced stages and was associated with large-cell transformation. Consistently with this observation, STAT3 activation occurred in parallel with MF progression in two initially MF-negative cases. A significant association of NFAT with NF-κB markers was also found, reflecting a common mechanism of activation in the two pathways. Genomic studies identified nine mutations in seven genes known to play a potential role in tumorigenesis in T-cell leukaemia/lymphoma, including PLCG1, JAK3 and STAT3, which underlies the activation of these key cell-survival pathways. A higher mutational allele frequency was detected in advanced stages.

CONCLUSIONS

Our results show that STAT3 is activated in advanced cases and is associated with large-cell transformation, while the activation of NFAT and NF-κB is maintained throughout the disease. These findings could have important diagnostic and therapeutic implications. What's already known about this topic? Mycosis fungoides is characterized by a clonal expansion of T cells in the skin. The mechanisms controlling disease development and progression are not fully understood. What does this study add? An association of the nuclear factor of activated T cells and nuclear factor kappa B pathways was found, which could reflect a common mechanism of activation. These pathways were activated in early and advanced stages at the same level. Signal transducer and activator of transcription 3 activation was associated with large-cell transformation and was more frequent in advanced stages. A genomic analysis of cutaneous T-cell lymphoma-associated genes was performed. Nine mutations were detected. What is the translational message? These results could have important implications for the treatment of MF in the near future.

摘要

背景

控制皮肤T细胞淋巴瘤(CTCL)发展的恶性机制正逐渐被识别。最近的证据表明,特定细胞内信号通路的紊乱,如RAS-丝裂原活化蛋白激酶、T细胞受体(TCR)-磷脂酶Cγ1(PLCG1)-活化T细胞核因子(NFAT)和Janus激酶(JAK)-信号转导及转录激活因子(STAT),可能在CTCL的发病机制中起关键作用。

目的

研究蕈样肉芽肿(MF)(CTCL最常见的形式)中控制疾病发展和进展的机制。

方法

我们收集了2001年至2018年间提交用于MF诊断或二次诊断的100份样本,其中80%处于疾病的早期临床阶段。福尔马林固定石蜡包埋组织用于组织学检查,并通过免疫组化测量TCR-PLCG1-NFAT、JAK-STAT和NF-κB信号通路激活的替代标志物的表达。还检查了亲毛囊性和大细胞转化情况。

结果

NFAT和核因子κB(NF-κB)标志物在早期和晚期显示出相当的激活状态,而STAT3激活在晚期更频繁,且与大细胞转化相关。与该观察结果一致,在两个最初MF阴性的病例中,STAT3激活与MF进展同时发生。还发现NFAT与NF-κB标志物之间存在显著关联,反映了两条信号通路激活的共同机制。基因组研究在已知在T细胞白血病/淋巴瘤肿瘤发生中起潜在作用的7个基因中鉴定出9个突变,包括PLCG1、JAK3和STAT3,这些突变是这些关键细胞存活信号通路激活的基础。在晚期检测到更高的突变等位基因频率。

结论

我们的结果表明,STAT3在晚期病例中被激活并与大细胞转化相关,而NFAT和NF-κB的激活在整个疾病过程中持续存在。这些发现可能具有重要的诊断和治疗意义。关于该主题已知的信息有哪些?蕈样肉芽肿的特征是皮肤中T细胞的克隆性扩增。控制疾病发展和进展的机制尚未完全了解。本研究增加了什么?发现了活化T细胞核因子和核因子κB信号通路之间的关联,这可能反映了一种共同的激活机制。这些信号通路在早期和晚期以相同水平被激活。信号转导及转录激活因子3激活与大细胞转化相关,且在晚期更频繁。对皮肤T细胞淋巴瘤相关基因进行了基因组分析。检测到9个突变。转化信息是什么?这些结果可能在不久的将来对MF的治疗具有重要意义。

相似文献

1
Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways.晚期蕈样肉芽肿:信号转导和转录激活因子3、核因子κB及活化T细胞核因子通路的作用
Br J Dermatol. 2020 Jan;182(1):147-155. doi: 10.1111/bjd.18098. Epub 2019 Jul 25.
2
Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis.核因子-κB的组成性表达是蕈样肉芽肿的一个特征:对凋亡抵抗和发病机制的影响。
Hum Pathol. 2000 Dec;31(12):1482-90. doi: 10.1053/hupa.2000.20370.
3
Mapping signal transducer and activator of transcription (STAT) activity in different stages of mycosis fungoides and Sezary syndrome.检测蕈样肉芽肿和塞扎里综合征不同阶段信号转导和转录激活因子(STAT)的活性。
Int J Dermatol. 2020 Sep;59(9):1106-1112. doi: 10.1111/ijd.15036. Epub 2020 Jul 8.
4
Molecular advances in cutaneous T-cell lymphoma.皮肤T细胞淋巴瘤的分子进展
Semin Cutan Med Surg. 2018 Mar;37(1):81-86. doi: 10.12788/j.sder.2018.007.
5
Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.Jak3、STAT3和STAT5抑制皮肤T细胞淋巴瘤中一种新型肿瘤抑制性微小RNA——miR-22的表达。
Oncotarget. 2015 Aug 21;6(24):20555-69. doi: 10.18632/oncotarget.4111.
6
Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma.正常成纤维细胞和癌细胞在皮肤 T 细胞淋巴瘤中差异调节 TWIST1、TOX 和细胞因子基因的表达。
BMC Cancer. 2021 May 3;21(1):492. doi: 10.1186/s12885-021-08142-7.
7
PLCG1 mutations in cutaneous T-cell lymphomas.PLCG1 基因突变与皮肤 T 细胞淋巴瘤。
Blood. 2014 Mar 27;123(13):2034-43. doi: 10.1182/blood-2013-05-504308. Epub 2014 Feb 4.
8
Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma.抑癌 microRNA-124 的表观遗传沉默直接支持皮肤 T 细胞淋巴瘤中 STAT3 的激活。
Cells. 2020 Dec 15;9(12):2692. doi: 10.3390/cells9122692.
9
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.原发性皮肤 T 细胞淋巴瘤(蕈样肉芽肿和赛泽里综合征):第一部分。诊断:临床和组织病理学特征以及新的分子和生物学标志物。
J Am Acad Dermatol. 2014 Feb;70(2):205.e1-16; quiz 221-2. doi: 10.1016/j.jaad.2013.07.049.
10
In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3.皮肤T细胞淋巴瘤中STAT3的体内激活。STAT3抗凋亡功能的证据。
Leukemia. 2004 Jul;18(7):1288-95. doi: 10.1038/sj.leu.2403385.

引用本文的文献

1
Rapid Progression of Cutaneous Lymphoma Following mRNA COVID-19 Vaccination: A Case Report and Pathogenetic Insights.mRNA新冠疫苗接种后皮肤淋巴瘤的快速进展:一例报告及发病机制见解
Vaccines (Basel). 2025 Jun 25;13(7):678. doi: 10.3390/vaccines13070678.
2
A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.一个患者来源的T细胞淋巴瘤生物样本库揭示了致病机制和宿主相关的治疗弱点。
Cell Rep Med. 2025 Apr 15;6(4):102029. doi: 10.1016/j.xcrm.2025.102029. Epub 2025 Mar 26.
3
Elucidation of -derived natural compounds in STAT 3 pathway against human cancer cells: and studies.
阐明STAT 3信号通路中针对人类癌细胞的源自-的天然化合物:和研究。 (注:原文中“-derived”处有信息缺失,翻译可能不太准确完整)
Front Pharmacol. 2025 Feb 21;16:1507002. doi: 10.3389/fphar.2025.1507002. eCollection 2025.
4
Therapeutic Targeting of the Janus Kinase/Signal Transducer and Activator of Transcription Pathway in Cutaneous T-Cell Lymphoma.皮肤T细胞淋巴瘤中Janus激酶/信号转导及转录激活因子通路的治疗靶向作用
Cancers (Basel). 2025 Feb 7;17(4):568. doi: 10.3390/cancers17040568.
5
Multi-Omic Data Integration Suggests Putative Microbial Drivers of Aetiopathogenesis in Mycosis Fungoides.多组学数据整合提示蕈样肉芽肿发病机制中可能的微生物驱动因素。
Cancers (Basel). 2024 Nov 25;16(23):3947. doi: 10.3390/cancers16233947.
6
JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature.JAK抑制剂在皮肤T细胞淋巴瘤中的作用:是友是敌?已发表文献的系统评价
Cancers (Basel). 2024 Feb 21;16(5):861. doi: 10.3390/cancers16050861.
7
Role of IL-4 and IL-13 in Cutaneous T Cell Lymphoma.白细胞介素-4和白细胞介素-13在皮肤T细胞淋巴瘤中的作用
Life (Basel). 2024 Feb 9;14(2):245. doi: 10.3390/life14020245.
8
Targeting STAT3 Enzyme for Cancer Treatment.靶向STAT3酶用于癌症治疗。
Mini Rev Med Chem. 2024;24(13):1252-1261. doi: 10.2174/0113895575254012231024062619.
9
Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma.抗 PD-L1 和来那度胺重编程 PD-1+M2 样肿瘤相关巨噬细胞治疗皮肤 T 细胞淋巴瘤。
JCI Insight. 2023 Jul 10;8(13):e163518. doi: 10.1172/jci.insight.163518.
10
Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study.富马酸二甲酯治疗复发/难治性皮肤 T 细胞淋巴瘤:一项多中心 2 期研究。
Blood. 2023 Aug 31;142(9):794-805. doi: 10.1182/blood.2022018669.